Aluminum Pharmaceutical Bottle OEM: CRC Child-Resistant Closure for OTC Liquid Medicines

⚡ TL;DR — Key Takeaways

• CRC (child-resistant closure) push-and-turn caps reduce accidental pediatric ingestion of OTC liquid medicines by 45–70% compared to standard continuous-thread closures—and in the United States, 16 CFR Part 1700 mandates CRC packaging for any OTC oral drug containing more than 66 mg of elemental iron per package or any product regulated under the Poison Prevention Packaging Act of 1970.
• Aluminum pharmaceutical bottles with epoxy-phenolic internal lacquer (20–30 μm dry film thickness) prevent metal-ion leaching into liquid drug formulations for 36+ months of shelf life, outperforming HDPE containers in oxygen barrier by 15–20× and providing 100% UV opacity that protects light-sensitive active pharmaceutical ingredients (APIs) such as diphenhydramine, dextromethorphan, and guaifenesin.
• OEM aluminum pharmaceutical bottle manufacturers offering in-house decoration (silk-screen + hot-stamp + UV digital printing) can reduce per-unit costs by 12–18% at 50,000-unit volumes compared to sourcing bottles and decorations from separate vendors, because the OEM consolidates quality control, eliminates redundant logistics markups, and avoids the compatibility testing that consumes 6–8 weeks when switching decoration suppliers.
• CRC cap designs must pass ISO 8317 / 16 CFR 1700.20 panel testing with a child-resistant effectiveness (CRE) of ≥85% for children aged 42–51 months and senior-use effectiveness (SUE) of ≥90% for adults aged 50–70—a testing protocol that typically adds 4–6 weeks and $3,000–$8,000 to the first-article qualification timeline.
• The total landed cost for a 100 ml aluminum pharmaceutical bottle with CRC cap, internal lacquer, and 2-color silk-screen decoration at 50,000-unit OEM volumes runs $0.72–$1.05 FOB Ningbo, placing it between standard HDPE ($0.18–$0.35) and Type III soda-lime glass ($0.90–$1.40) on the pharmaceutical packaging cost spectrum.

We have spent enough years on pharmaceutical packaging production lines to know one thing with certainty: the package is part of the drug product. It is not an afterthought, not a procurement checkbox, and not a commodity item to be sourced from the lowest bidder without qualification. When a parent discovers their three-year-old has opened a bottle of acetaminophen elixir, the failure is not in the drug formulation—it is in the closure, the bottle, and the quality system that approved them for production.

For OTC drug brands and contract manufacturers sourcing aluminum pharmaceutical bottle OEMwith CRC child-resistant closures, the procurement decision is simultaneously a regulatory compliance decision, a liability management decision, and a brand-perception decision. In this guide, we walk through every specification, test protocol, material selection, and cost factor that pharmaceutical packaging buyers need to evaluate when selecting an OEM Aluminum Bottle partner for OTC liquid medicines.

Why Aluminum for Pharmaceutical Liquid Packaging? Barrier Performance and Regulatory Logic

The first question most pharmaceutical packaging buyers ask is straightforward: why aluminum instead of glass or HDPE? The answer lives at the intersection of three concerns—API stability, child safety, and supply-chain economics.

Answer Nugget: An unpigmented HDPE bottle with 0.8 mm wall thickness permits approximately 120–180 cm³·mil/(m²·day·atm) of oxygen transmission at 23°C and 50% RH. An aluminum bottle with 0.3 mm wall thickness and internal lacquer delivers oxygen transmission below 0.05 cm³/(m²·day·atm)—a barrier improvement of 2,400–3,600×. For oxidation-prone liquid APIs such as diphenhydramine HCl, this barrier differential translates directly into shelf-life extension from 18–24 months in HDPE to 36–48 months in lacquered aluminum.

The UV protection is equally critical. Many OTC liquid formulations—children's cough/cold syrups containing dextromethorphan, antihistamine syrups with diphenhydramine, and expectorant solutions with guaifenesin—undergo photodegradation when exposed to UV wavelengths below 400 nm. Aluminum's 100% UV opacity eliminates this degradation pathway entirely, while amber glass achieves approximately 85–92% UV blocking (still permitting some visible-spectrum photoactivity) and unpigmented HDPE provides essentially zero UV protection without opaque colorant loading that complicates recycling streams.

We should also address the weight and breakage advantage. A filled 118 ml (4 fl oz) aluminum pharmaceutical bottle with CRC cap weighs 56–68 grams compared to 148–175 grams for the equivalent Type III glass bottle with CRC cap. For a 50,000-unit shipment from Ningbo to a US East Coast distribution center, that weight differential saves approximately 4.5–5.3 metric tons of shipping weight—enough to reduce freight costs by $2,800–$4,200 per container while simultaneously eliminating the 2–5% breakage rate that glass pharmaceutical bottles incur during international container shipping.

Answer Nugget: The FDA's 21 CFR 211.94 (Drug Product Containers and Closures) requires that container closure systems provide adequate protection against foreseeable external factors that can cause deterioration or contamination. An aluminum bottle with qualified internal lacquer and a validated CRC closure satisfies this requirement for liquid OTC drugs, but only when the OEM provides a full drug master file (DMF) Type III submission package documenting lacquer formulation, cure cycle parameters, extractables/leachables testing per USP <661.1> and USP <661.2>, and CRC effectiveness certification per 16 CFR 1700.20.

CRC Child-Resistant Closure: Design Principles and Testing Standards

The child-resistant closure is the most regulated component in pharmaceutical packaging—and for good reason. According to the CDC's National Electronic Injury Surveillance System, approximately 60,000 young children are treated in US emergency departments annually for unsupervised medication ingestion, with over 70% of these incidents involving OTC products found in accessible packaging. CRC closures are the primary engineering control against this exposure pathway.

Push-and-Turn CRC Mechanism: How It Works

The push-and-turn CRC closure is the dominant design for aluminum pharmaceutical bottles in the OTC liquid medicine segment. It combines a two-motion opening sequence—simultaneous downward axial force (push) plus rotational torque (turn)—that exceeds the cognitive and motor capabilities of most children under 5 years of age while remaining operable by adults with normal dexterity.

Key Technical Parameters:

• Axial force to engage (push): 15–25 N (ISO 8317 Annex B)
• Rotational torque to open (turn): 0.8–1.5 N·m (ISO 8317 Annex B)
• Child-resistant effectiveness (CRE): ≥85% child panel (16 CFR 1700.20 / ISO 8317)
• Senior-use effectiveness (SUE): ≥90% adult panel 50–70 yr (16 CFR 1700.20 / ISO 8317)
• Cap material: PP (polypropylene) with HDPE inner liner (USP <661.1> / USP <661.2>)
• Induction seal liner: Aluminum foil / PET / PE triplex, 0.6–1.2 mm, tamper-evident per 21 CFR 211.132
• Neck finish: GPI 400, 410, or 415 finish (standardized), PPPA-compatible closures
• Opening cycles (rated): 200+ before torque degradation

Answer Nugget: CRC certification testing under 16 CFR 1700.20 requires a panel of 200 children (50 per age group at 42–44, 45–48, 49–51, and 52–54 months) and 100 older adults (50–70 years, with 70% female to reflect the demographic most likely to administer OTC medicines to children). The test protocol includes a 5-minute first-attempt period without demonstration, followed by a demonstration and a second 5-minute period. A package passes if ≥85% of children fail to open it (without demonstration) AND ≥90% of adults succeed (after demonstration). This is not a "design review" standard—it is a live-participant human factors test that must be repeated whenever the closure design, material, or manufacturing process changes.

The Induction Seal: Tamper Evidence Meets Child Resistance

An often-overlooked layer in the CRC system is the induction seal liner. 21 CFR 211.132 mandates tamper-evident packaging for all OTC drug products, and in the aluminum bottle + CRC cap system, the induction seal serves dual duty: it is the primary tamper-evident feature that the consumer visually inspects upon first opening, and it provides the initial airtight barrier that protects the drug product from the moment of filling until the consumer breaks the seal.

We specify a triplex laminate (aluminum foil / PET / LDPE) with a minimum foil thickness of 35 μm and a heat-seal coating activated at 180–220°C for 1.5–3.0 seconds during the induction sealing process. The critical performance parameter is seal integrity at −20 kPa differential pressure for 5 minutes without leakage—a test we perform on a statistical sampling basis (AQL 0.65, Level II per ISO 2859-1) for every production lot.

Internal Lacquer Coating: The Pharmacopoeia-Compliant Barrier

We have covered this topic extensively in our cosmetic packaging guides, but pharmaceutical applications impose a different compliance framework that deserves dedicated treatment. The internal lacquer coating on an aluminum pharmaceutical bottle must satisfy two bodies of regulation simultaneously: food-contact materials regulation (EU 1935/2004, FDA 21 CFR 175.300) for general safety, and pharmaceutical packaging regulation (USP <661.1> and <661.2>, EP 3.1, JP 7.02) for drug product compatibility.

Lacquer Selection per Formulation Type:

• Aqueous syrups (pH 4–7): Epoxy-phenolic, 15–20 μm, 200–210°C cure, 10–12 min. Concern: water absorption, pH-driven delamination.
• Alcohol-containing elixirs (5–20% ethanol): Epoxy-phenolic (high crosslink), 20–25 μm, 210–220°C cure, 12–15 min. Concern: solvent swelling, plasticizer migration.
• Glycerin-based pediatric formulations: Epoxy-phenolic with PTFE modifier, 20–30 μm, 215–225°C cure, 12–15 min. Concern: viscosity-related coating stress.
• Oil-based vitamin/mineral suspensions: Epoxy-amino (amine-cured), 18–25 μm, 195–205°C cure, 10–14 min. Concern: free fatty acid corrosion.
• Citrate-buffered formulations (pH 2.5–4): Phenolic-epoxy (acid-resistant grade), 25–35 μm, 215–230°C cure, 15–18 min. Concern: acid-induced aluminum dissolution.

Answer Nugget: Extractables and leachables (E&L) testing for pharmaceutical aluminum bottles is governed by USP <1663> (Assessment of Extractables Associated with Pharmaceutical Packaging/Delivery Systems) and USP <1664> (Assessment of Drug Product Leachables). The OEM must provide an extractables profile generated under exaggerated conditions (typically 40°C / 75% RH for 6 months, or 50°C for 3 months as accelerated equivalent), identifying every chemical species that migrates from the lacquer into the drug product simulant at concentrations above the analytical evaluation threshold (AET) of 5 μg/day for an orally administered drug product. This data package typically runs 80–150 pages and represents $15,000–$35,000 in contracted laboratory testing.

A single undetected pinhole in the internal lacquer—even one as small as 25–50 μm in diameter—can create a localized corrosion cell that releases aluminum ions (Al³⁺) into the drug solution at rates of 0.1–0.5 mg per liter per month. While aluminum exposure limits for oral drug products are not specifically codified in USP, the WHO and FDA have established a provisional tolerable weekly intake (PTWI) of 1 mg/kg body weight for aluminum from all sources, and pharmaceutical manufacturers carry the burden of demonstrating that their container-closure system does not cause the drug product to exceed this threshold under labeled storage conditions. We perform 100% conductivity-based pinhole inspection (not statistical sampling) on every bottle in pharmaceutical-grade production lots, a practice that adds $0.015–$0.025 per bottle but eliminates the most common root cause of aluminum pharmaceutical container failure.

OEM Decoration: Regulatory Labeling Meets Brand Identity

Pharmaceutical labeling is not cosmetic decoration—it is regulated information delivery governed by 21 CFR Part 201 (Drug Labeling) in the US and Directive 2001/83/EC (as amended by 2011/62/EU for falsified medicines) in the EU. When we talk about OEM aluminum pharmaceutical bottle decoration, we are discussing the integration of mandatory drug facts panels, lot numbers, expiration dates, NDC codes, and barcodes into the bottle surface—not just brand colors and logos.

Decoration Technology Comparison:

• Silk-screen (1–3 colors): 120–150 LPI, Pantone solid, excellent durability, MOQ 5,000, $0.04–$0.12/unit at 50K
• Hot-stamp foil: Up to 200 LPI, metallic only, excellent durability, MOQ 3,000, $0.06–$0.15/unit at 50K
• UV digital printing: 600–1200 DPI, CMYK + white, good durability, MOQ 500, $0.15–$0.35/unit at 50K, supports variable data
• Shrink-sleeve label: 300 DPI, full color, good durability, MOQ 2,000, $0.08–$0.20/unit at 50K, supports variable data
• Embossing/debossing: Tactile/substrate color, permanent, MOQ 10,000, $0.10–$0.25/unit at 50K

Answer Nugget: The most cost-effective decoration strategy for OTC pharmaceutical aluminum bottles at 50,000+ unit volumes combines 2-color silk-screen (drug facts panel in black, brand logo in brand color) with hot-stamp foil for the product name and strength statement. This three-process decoration stack adds approximately $0.18–$0.28 per bottle at 50,000 units while achieving the visual premium quality expected for pharmacy-shelf products. UV digital printing, while more expensive per unit, becomes the preferred choice for products with multiple SKU variants (different strengths, flavors, or package sizes) because it eliminates separate screen and stamp tooling for each variant—at 5+ SKU variants, the tooling savings offset the higher per-unit print cost.

Aluminum Bottle Manufacturing: From Aluminum Slug to Finished Pharmaceutical Container

The manufacturing process for aluminum pharmaceutical bottles is impact extrusion—a cold-forming process that converts a precisely weighed aluminum slug (typically 99.5–99.7% pure aluminum, alloy 1070 or 1050) into a seamless, single-piece bottle body in a single press stroke. This process produces a bottle with zero weld seams, uniform wall thickness (tolerance ±0.05 mm on 0.3 mm nominal wall), and a grain-structure alignment that follows the bottle contour—all characteristics that contribute to the container's mechanical integrity and barrier uniformity.

The critical process parameters we control at our Ningbo facility include:

1. Slug weight tolerance: ±0.3% of target weight. Variation in slug weight directly translates into variation in wall thickness at the bottle shoulder and base radii—the two zones most susceptible to stress-cracking under drop-impact conditions.
2. Extrusion die temperature: 150–180°C, maintained by closed-loop oil-temperature control. Die temperature affects aluminum flow viscosity and determines the surface finish of the bottle interior—a rougher interior surface creates more lacquer-anchoring surface area but also provides more sites for pinhole formation during the cure cycle.
3. Annealing cycle: 340–380°C for 2–4 hours post-extrusion, followed by controlled cooling at 20–30°C/hour. Annealing relieves the work-hardening introduced by cold forming and restores the ductility necessary for the bottle to deform rather than fracture under impact—critical for drop-test compliance per ISTA 3A.
4. Internal lacquer application: Electrostatic spray deposition at 60–80 kV, achieving a minimum 98% transfer efficiency onto the bottle interior. The spray pattern is validated for each bottle geometry using a UV-tracer lacquer sample that is sectioned and measured at 12 points around the circumference at 3 vertical positions (shoulder, body midpoint, base) to confirm film thickness uniformity.

Answer Nugget: The dimensional consistency achievable with impact-extruded aluminum bottles (body diameter ±0.2 mm, height ±0.5 mm, neck finish within GPI standard tolerance) enables high-speed filling line compatibility at rates of 120–200 bottles per minute. This is a key advantage over blown glass pharmaceutical bottles, whose dimensional variability (±1.0–1.5 mm on body diameter) forces filling lines to run slower (60–100 bpm) with higher jam and rejection rates. For a contract manufacturer filling 10 million units annually, the throughput differential alone saves $80,000–$150,000 per year in line-time costs.

Quality Control and Regulatory Documentation Package

Sourcing an aluminum pharmaceutical bottle OEM is not a transaction—it is the initiation of a supplier quality relationship that will be audited by your quality assurance team, potentially by FDA investigators, and certainly by your product liability insurer. The OEM's quality documentation package is the primary instrument of that relationship.

The minimum documentation package we provide for pharmaceutical-grade aluminum bottle orders includes:

• DMF Type III (Drug Master File for Packaging Materials): Filed with the FDA, containing the complete formulation, manufacturing process, quality control specifications, and stability data for the aluminum bottle, internal lacquer, and CRC closure system.
• Certificate of Analysis (CoA) per production lot: Documenting dimensional inspection results, lacquer film thickness measurements, pinhole detection results, CRC cap torque values, induction seal integrity test results, and visual inspection acceptance rates.
• Certificate of Conformance (CoC): Attesting compliance with 21 CFR 175.300, USP <661.1> and <661.2>, EU 1935/2004 and EU 10/2011, and 16 CFR 1700.20.
• Extractables and leachables study report: Full USP <1663>/<1664> compliant study with GC-MS, LC-MS, and ICP-MS analysis, conducted by an ISO 17025-accredited third-party laboratory.
• Stability study data: Accelerated (40°C/75% RH, 6 months) and real-time (25°C/60% RH, 24–36 months) storage data demonstrating lacquer integrity, closure torque retention, and seal integrity maintenance over labeled shelf life.
• ISO 9001:2015 and ISO 15378:2017 certifications: The latter specifically addresses GMP requirements for primary packaging materials for medicinal products.

Answer Nugget: A complete pharmaceutical aluminum bottle OEM qualification—from initial supplier audit through first-article approval to commercial production release—typically requires 6–9 months. The critical-path items are the extractables/leachables study (3–4 months for accelerated conditions), the CRC panel test (4–6 weeks from sample availability to test report), and the drug product stability study incorporating the qualified packaging (6 months accelerated minimum). Buyers who compress this timeline risk receiving an incomplete regulatory package that will delay ANDA/NDA approval or trigger a Form 483 observation during a FDA pre-approval inspection.

Cost Structure: What Determines Aluminum Pharmaceutical Bottle OEM Pricing

We find that pharmaceutical packaging buyers often enter OEM negotiations with a simplified per-unit price comparison that misses 40–60% of the total cost of ownership. The fully loaded cost of an aluminum pharmaceutical bottle includes not just the FOB unit price, but also qualifiable documentation costs, CRC testing amortization, line trial expenses, and the ongoing cost of quality (CoQ) represented by incoming inspection, retained samples, and annual requalification.

Cost Breakdown (50,000 units, 100 ml bottle):

• Aluminum bottle (impact-extruded, lacquered): $0.38–$0.55 (45–55% of total). Includes 1070-grade slug, extrusion, annealing, electrostatic lacquer application.
• CRC push-and-turn cap with induction liner: $0.12–$0.22 (15–20%). PP cap body, HDPE inner shell, triplex induction seal liner.
• Decoration (2-color silk-screen + hot-stamp): $0.12–$0.22 (15–20%). Includes screen prep, color matching, foil die fabrication amortized over 50K.
• Quality documentation package: $0.04–$0.08 (5–8%). CoA/CoC/CoT per lot, retained samples, stability retain program.
• CRC panel testing (amortized): $0.02–$0.05 (3–5%). Initial certification + annual requalification over first-year volume.
• Packaging and palletization: $0.04–$0.08 (5–8%). PE bag inner, corrugated export carton, pallet + stretch wrap.
• Total FOB Ningbo: $0.72–$1.20 (100%). Excludes sea freight, import duties, and US domestic distribution.

Passenpack's approach to pharmaceutical aluminum bottle OEM integrates bottle manufacturing, lacquer application, CRC cap sourcing, and multi-process decoration under a single quality management system. For OTC drug brands and contract manufacturers who want to explore aluminum pharmaceutical packaging options, we recommend starting with our OEM aluminum airless bottles category to understand our aluminum forming and coating capabilities, then reviewing our full aluminum packaging products range to identify standard bottle shapes that can be adapted to pharmaceutical-grade specifications with the appropriate lacquer, closure, and decoration combination for your drug product.

FAQ: Aluminum Pharmaceutical Bottle OEM with CRC Closures

Q: Does every OTC liquid medicine require CRC packaging?
A: Under 16 CFR Part 1700, any OTC oral drug product containing more than 66 mg of elemental iron per package must use CRC packaging. Additionally, any product that the CPSC has specifically listed as requiring special packaging—including acetaminophen, ibuprofen, diphenhydramine, loperamide, and aspirin-containing products in liquid form—requires CRC compliance. One exception: manufacturers may offer a single non-CRC package size for elderly or handicapped consumers, provided it is labeled "This Package for Households Without Young Children" per 16 CFR 1700.5. For products distributed in the EU, Directive 2001/83/EC as amended by 2011/62/EU requires CRC closures for all products containing substances listed in Annex I of the directive. We always recommend legal review of your specific product formulation against current regulatory requirements before finalizing packaging specifications.

Q: What is the minimum order quantity for OEM aluminum pharmaceutical bottles with CRC caps?
A: For standard aluminum bottle shapes (24/410 or 28/410 neck finish) with certified CRC push-and-turn caps, MOQs typically start at 10,000 units per size/cap combination. Custom bottle shapes requiring new impact-extrusion dies add 15,000–20,000 units to the MOQ to amortize tooling costs ($8,000–$15,000 for extrusion die sets). Custom lacquer formulations for specific drug product compatibility add 20,000–30,000 units because of the minimum lacquer batch size (typically 50–100 liters of custom-formulated coating) and the validation-sampling requirements. We recommend starting with our standard aluminum bottle shapes and standard lacquer formulations for initial qualification, then transitioning to custom tooling and custom lacquers for commercial-scale production once the drug product-packaging compatibility is confirmed.

Q: How long does CRC certification testing take, and can I use a previously certified closure on a different bottle?
A: CRC certification panel testing per 16 CFR 1700.20 or ISO 8317 requires 4–6 weeks from sample submission to test report issuance, assuming no scheduling delays at the testing laboratory. Critically, CRC certification is specific to the exact closure-bottle combination tested—you cannot transfer a CRC certification from one bottle design to another, even if the closure is identical, because the bottle's neck finish geometry, wall stiffness, and overall size affect the ergonomics of the push-and-turn motion that the panel test evaluates. A closure certified on a 100 ml aluminum bottle with a 24/410 neck finish does not automatically qualify for a 200 ml bottle with the same neck finish if the larger bottle diameter changes the grip ergonomics. We strongly recommend performing a bridging study (reduced panel size, typically 50 children and 50 seniors) when changing bottle size within an existing qualified closure family.

Q: Can aluminum pharmaceutical bottles be sterilized for aseptic filling applications?
A: Yes, aluminum bottles with epoxy-phenolic internal lacquer can withstand gamma irradiation sterilization at 25–40 kGy (typical dose for pharmaceutical products), ethylene oxide (EtO) sterilization at 55°C, and—for specific high-temperature lacquer formulations—steam sterilization at 121°C for 15–20 minutes. However, each sterilization method introduces distinct risks: gamma irradiation at doses above 50 kGy can cause yellowing and embrittlement of PP CRC caps; EtO sterilization requires extended aeration (24–48 hours at 50°C) to reduce residual EtO below the USP <77> limit of 5 ppm; and steam sterilization can cause lacquer delamination if the coating was applied below the minimum cure temperature. We validate sterilization compatibility on a case-by-case basis with the specific bottle-lacquer-cap combination and the customer's sterilization cycle parameters.

Q: What lead time should I plan for a first-order pharmaceutical aluminum bottle OEM project?
A: Plan for 4–5 months from PO issuance to first shipment for a standard aluminum bottle with qualified CRC closure and standard epoxy-phenolic lacquer. This timeline breaks down as: 2–3 weeks for artwork and decoration proof approval; 3–4 weeks for production of bottles and caps; 2–3 weeks for decoration setup and sample approval (including color-matching iterations); 2 weeks for quality documentation package preparation (CoA/CoC/DMF LOA); and 3–4 weeks for container loading and transit to port. Custom bottle tooling adds 6–8 weeks to this timeline; custom lacquer formulation adds 8–12 weeks including the accelerated compatibility testing cycle. We recommend initiating the OEM engagement at least 7–9 months before your planned first commercial filling date to accommodate the inevitable iterations in decoration, documentation, and compatibility testing.

Q: Are aluminum pharmaceutical bottles recyclable, and how does that affect sustainability reporting?
A: Aluminum is infinitely recyclable without loss of material properties, and recycling aluminum requires only 5% of the energy needed for primary aluminum production—a fact that makes aluminum pharmaceutical bottles highly attractive from a Scope 3 emissions perspective. However, pharmaceutical aluminum bottles face two recycling-stream challenges: (1) the internal lacquer coating and induction seal residue are contaminants in the aluminum recycling melt that must be burned off during remelting (contributing approximately 0.5–1.5% mass loss), and (2) post-consumer pharmaceutical packaging is typically classified as hazardous or medical waste in most municipal waste streams, diverting it from standard aluminum recycling channels. For sustainability reporting, we recommend using the Aluminum Association's Environmental Product Declaration (EPD) data for impact-extruded aluminum containers, with a recycling content claim based on the average 65–75% post-industrial recycled content in 1070-grade aluminum slug stock. We provide full material traceability documentation to support your product-level lifecycle assessment (LCA) and sustainability reporting.

Looking for aluminum pharmaceutical bottle OEM with certified CRC child-resistant closures? Contact Passenpack for factory-direct aluminum bottles with USP-compliant lacquers, PPPA-certified CRC caps, and integrated decoration—supported by a complete FDA DMF Type III documentation package. ISO 9001 / ISO 15378 certified manufacturing in Ningbo, China. Request Pharmaceutical Packaging Quote →